Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAMPT | P43490 | 1/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.52 |
| ▸ | MAPT | P10636 | 5/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.48 |
| ▸ | MEN1 | O00255 | 2/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | CA1 | P00915 | 2/20 | 0.48 |
| ▸ | CA2 | P00918 | 2/20 | 0.48 |
| ▸ | CA9 | Q16790 | 2/20 | 0.48 |
| ▸ | CA7 | P43166 | 1/20 | 0.48 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | PKM | P14618 | 1/20 | 0.48 |
| ▸ | CA12 | O43570 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4517553 | 1.00 | NAMPT (0.57) | NAMPTSMN1; SMN2ALDH1A1MAPTGAA | |
| SCHEMBL4517549 | 1.00 | NAMPT (0.57) | NAMPTSMN1; SMN2ALDH1A1MAPTGAA | |
| SCHEMBL4500655 | 0.91 | NAMPT (0.56) | NAMPTSMN1; SMN2ALDH1A1MAPTKMT2A | |
| SCHEMBL4500657 | 0.91 | NAMPT (0.56) | NAMPTSMN1; SMN2ALDH1A1MAPTKMT2A | |
| SCHEMBL4500659 | 0.91 | NAMPT (0.56) | NAMPTSMN1; SMN2ALDH1A1MAPTKMT2A | |
| SCHEMBL4501984 | 0.84 | SMN1; SMN2 (0.49) | NAMPTSMN1; SMN2ALDH1A1MAPTGAA | |
| SCHEMBL4501981 | 0.84 | SMN1; SMN2 (0.49) | NAMPTSMN1; SMN2ALDH1A1MAPTGAA | |
| SCHEMBL4501966 | 0.84 | SMN1; SMN2 (0.49) | NAMPTSMN1; SMN2ALDH1A1MAPTGAA | |
| SCHEMBL12057135 | 0.79 | MAPT (0.52) | NAMPTSMN1; SMN2ALDH1A1MAPTGAA | |
| SCHEMBL4506447 | 0.75 | CYSLTR2 (0.51) | SMN1; SMN2ALDH1A1MAPTGAAKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7638540-B2 | Benzofuran compound and medicinal composition containing the same | THE NEW INDUSTRY RESEARCH ORGANIZATION (JP) | 2009-12-29 | — | — | US | disclosed |
| US-7638540-B2 | Benzofuran compound and medicinal composition containing the same | THE NEW INDUSTRY RESEARCH ORGANIZATION (JP) | 2009-12-29 | — | — | US | disclosed |
| US-7638540-B2 | Benzofuran compound and medicinal composition containing the same | THE NEW INDUSTRY RESEARCH ORGANIZATION (JP) | 2009-12-29 | — | — | US | disclosed |
| US-20060194851-A1 | Benzofuran compound and medicinal composition containing the same | NEW INDUSTRY RESEARCH ORGANIZATION, THE (JP) | 2006-08-31 | — | — | US | disclosed |
| EP-1627873-A1 | BENZOFURAN COMPOUND AND MEDICINAL COMPOSITION CONTAINING THE SAME | The New Industry Research Organization (JP) | 2006-02-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060194851-A1 | Benzofuran compound and medicinal composition containing the same | LTB4R2, LTC4S, LTB4R | NAMPT 141/4885SMN1; SMN2 2975/4885ALDH1A1 658/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.